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Abstract We have characterized somatostatinergic phenotype 
markers of the human neuroblastoma, LA-N-2. A single mRNA- 
transcript (~850bp) and two cellular somatostatin immunoreaetiv- 
ity forms, a high molecular weight form (Mr 15,000) and a frag- 
ment corresponding to somatostatin-28 was found, while the so- 
matostatin-14 peptide was absent. Saturation binding experi- 
ments demonstrated a single class of high-affinity somatostatin 
receptors with K d and Bma ~ of 0.27 - 0.03 nM and 45 + 1 fmol/mg 
protein. Partial G-protein uncoupling (30%) was demonstrated, 
using GTPyS, with an affinity of 9.7 nM. The LA-N-2 cell line, 
previously shown to be cholinergic, may serve as a simplified 
system to elucidate heterologous neurotransmittor interactions. 
Such studies are of interest since dysfunctions of the cholinergic 
basal forebrain neurons and somatostatin immunoreactive in- 
terneurons have been consistently observed in Aizheimer's dis- 
ease. 
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1. Introduction 
Somatostatin (SS-14) is a tetradecapeptide originally identi- 
fied in the hypothalamus as an inhibitory factor of growth 
hormone secretion [1]. Several SS-immunoreactive (SS-ir) pep- 
tides are derived from a common precursor molecule (proSS) 
through tissue-specific processing at dibasic or monobasic 
amino acids, in similarity to other neuropeptide systems. 
Prohormonal processing at the C-terminal segment generate 
two biologically active peptides, SS-14 and SS-28, as well as the 
non-somatostatin peptides pro-SS(1-76), pro-SS(1-64) and SS- 
28(1-12). More recently the peptide fragment antrin, proSS(1- 
10), derived through processing at the N-terminal portion of 
proSS has been described [2]. 
Although highest peptide concentrations are found in hy- 
pothalamic regions, such as the median eminence, later studies 
have revealed a much wider distribution of SS-ir neurons in the 
central nervous system (CNS) [3,4]. SS-containing neurons in 
the cerebral cortex and hippocampus has been suggested to 
influence cognitive functions, since this neuropeptide system is 
consistently affected in Alzheimer's disease [5]. Behavioral 
studies showing that transient depletion of central SS-ir with 
cysteamin impairs performance on passive avoidance retention 
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testing have strengthened this reasoning [6,7]. Neuropeptider- 
gic transmittors are generally classified as conveying slow sig- 
nalling with a prolonged modulating response, as opposed to 
classic transmittors with a rapid mode of action. Thus impaired 
functional state of a neuropeptidergic neuronal population 
might affect pre- or postsynaptical responses mediated by fast- 
acting neurotransmittors. Iontophoretic application of SS-14 
have been shown to enhance ACh-induced excitation in hip- 
pocampal and cortical cells [8]. SS-ir peptides have also been 
demonstrated to enhance K+-evoked release of acetylcholine, 
when applied exogenously to hippocampal s ice preparations 
[9]. 
Neuroblastoma cell lines may serve as a simplified model 
system to elucidate such molecular interactions with heterolo- 
gous neurotransmittor systems. The neuroblastoma cells con- 
stitute a clonal homogenous populations of cells, as opposed 
to the mature central nervous ystem which is highly complex 
with a large number of terminally differentiated neuronal and 
glial cell types. Furthermore the cell cultures can be grown 
indefinitely in vitro, which is advantageous compared to disso- 
ciated primary cell cultures and brain tissue explants. The aim 
of the present study was to identify a human neuroblastoma cell 
line expressing somatostatinergic phenotype markers. The neu- 
roblastoma, LA-N-2, was the only cell line found expressing 
preproSS-mRNA, SS-ir peptide fragments and [~25I]TyrJ LSS- 14 
binding sites, among a variety of differentiated and non-differ- 
entiated cells lines initially screened for preproSS-mRNA ex- 
pression. 
2. Materials and methods 
2.1. Cell culture 
The neuroblastoma cell line LA-N-2 (passage 117 125) was grown 
at 37°C in RPMI-1640 culture medium (GibcoBRL, Life Technologies, 
Scotland) supplemented with 10% fetal calf serum, L-glutamine 0.29 
mg/ml, penicillin 100 IU/ml and streptomycin 50/tg/ml in humidified 
air containing 5% CO2. The medium was exchanged every third day. 
Confluent cells (2 x 105 eells/cm 2)were washed once in ice-cold phos- 
phate-buffered saline (PBS; 137 mM NaCI, 10 mM NazHPO4, 1.6 mM 
NaH2PO 4, pH 7.4) supplemented with 10 mM EDTA and harvested in
ice-cold PBS-buffer. Pepstatin (1 /.tM; Boehringer) was supplemented 
to the PBS/EDTA solution when indicated. The cell pellet used for 
RNA preparation, radioimmunoassay and [125I]TyrH-SS-14 receptor 
binding was obtained by centifugation at 1000 × g for 5 rain at 25°C. 
2.2. Animals 
Adult male Sprague-Dawley rats (AIab, Sollentuna, Sweden) were 
kept on a 12 h on/12 h offlighting schedule in a room thermostaticly 
maintained at22 _+ I°C. Ad lib food (Lab Chow R36, Laktamin, Vad- 
stena, Sweden) and water was available. The animals were decapitated 
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and hypothalamic tissue, including the preoptic area, was rapidly dis- 
sected on ice and frozen on dry ice. 
2.3. RNA preparation and Northern blot analysis 
Total cellular RNA (~2 x 10 7 cells) were extracted [10] and checked 
for degradation by agarose gel electrophoresis and quantification of 
UV absorption at 260/280 nm. Total RNA (10/lg) was electrophoreti- 
cally separated on a 1.2% (w/v) agarose gel containing 0.7% (v/v) for- 
maldehyde gel in 1 x MOPS (1 × MOPS is 0.02M 3-N-morpholino- 
propanesulphonic acid, 8 mM sodium acetete, 1mM EDTA, pH 7.0) 
followed by transfer onto Amersham Hybond-N+-filter in 25 mM so- 
dium phosphate buffer (pH 6,4). Prehybridization was carried out for 
4 h at 65°C with 5 x SSPE (1 x SSPE in 0.15 M NaCI, 0.01 M Na2H2P04 
0.001 M EDTA, pH 7.4), 5 x Denhardt's solution, 0.5% sodium do- 
decylsulphate (SDS) and 20 ¢tg/ml heat denatured salmon sperm DNA. 
Hybridization was performed over night at 55°C with 4 x SSC (1 x SSC 
is 0.15 M NaC1, 0.015 M sodium citrate, pH 7.0), 0.02 M PBS, 50% 
formamide, 10% dextran sulphate, 1x Denhardt's solution, 1% sarco- 
syl. The 48mer oligodeoxynucleotide probe, complementary to amino 
acids 96-111 (98% homology to human prepro-SS-mRNA), was 3'-end- 
labeled with 3-'P-dCTP to a specific activity of~0.50 x 109 cpm/pg probe. 
The nylon membrane was subsequently washed 4 times (15 min in each 
cycle) at 65°C with 1 x SSC, 0.1% SDS. The bands were visualised by 
exposure for 24 h at -70°C against Amersham MP films, using a 
Amersham intensifying screens. 
2.4. Radioimmunoassay 
Pelleted cells (2.5 x 10%ells/ml 1M HAc) and hypothalamic rat tissue 
(10 v/w of 1 M HAc) were dissolved and boiled in heated acetic acid 
for 10 min, cooled on ice and centrifuged at 17,600 x g for 20 min at 
4°C. Pepstatin (0.15 mM; Boehringer) was supplemented to acetic acid 
when indicated. Aliquots of the supernatant were stored at -70°C. 
Hypothalamic tissue was homogenized with a teflon/glass homogenizer 
prior to centrifugation. The SS radioimmunoassay (RIA) was per- 
formed using a C-terminal-directed antisera (Amersham International 
plc, UK). [~25I]Tyr~ ~-SS-14 (3,500 cpm, 1.3 pg; Amersham Int. plc, UK) 
was used as tracer and somatostatin (Peninsula, Belmont, CA, USA) 
was used as standard. The samples and other substrates were diluted 
in 50 mM sodium phosphate buffer (pH 7.2) containing 10 mM EDTA 
and 0.5% bovine serum albumin. Sample or standard (25/11) was mixed 
with 100 pl of tracer and 100 pl of antisera nd incubated at 4°C for 
24 h. Separation of bound and free peptide was achieved by adding 200 
pl of a mixture containing 0.25% charcoal and 0.025% dextran T-70 in 
50 mM sodium phosphate buffer (pH 7.2). The mixture was incubated 
on ice for 10 min and centrifuged at 9,500 x g for 1 min. A fixed volume 
(350,ul) of the supernatant was measured in a T-counter. The detection 
limit (ED~) was approximately 1.5 fmol/tube for the SS RIA. 
2.5. Gel permeation chromatography 
Extracted samples were applied to a Sephadex G-50 column (super- 
fine, l l0x  1.5 cm) equilibrated with 0.1 M acetic acid at 4°C. The 
column was calibrated with the following molecular weight markers: 
dextran blue, cytochrome c, aprotinin, glucagon and sodium chloride. 
The samples were eluted with 0.1 M acetic acid at a flow rate of 8 ml/h. 
and collected in fractions of 2 ml for measurement of SS-ir. 
2.6. [~251]TyrH-somatostatin-14 receptor binding assay 
Pelleted cells (~ 108cells) were dissolved in 5 ml ice-cold 50 mM Tris- 
HCl (pH 7.4), homogenized with a glass-teflon homogenizer and centri- 
fuged at 700 x g for 10 min at 4°C. The supernatant was centrifuged 
at 14,000 x g for 30 min at 4°C and the pellet obtained resuspended in 
1 ml 50 mM Tris-buffer (pH 7.4) and frozen at -20°C until use in 
binding assays. Membrane suspensions were thawed and diluted in 5 ml 
ice-cold 50 mM Tris-HCl buffer (pH 7.4). The mixture was centrifuged 
at 11,000 x g for 30 min at 4°C and the pellet resuspended in fresh 
buffer to give a protein concentration f approximately 0.3 pg/pl. Dilu- 
tions of peptides and radioactive ligand were made in the incubation 
buffer which consisted of 50 mM Tris-HCl (pH 7.4) containing 0.5 mg/ 
ml bovine serum albumin (BSA), 5 mM MnC12 and 0.03 mg/ml baci- 
tracin. Binding assays were performed in precoated Eppendorf tubes 
(0.5 mg/ml BSA in redistilled water). Membrane preparation (-40/tg 
protein) and [~25I]Tyr~ ~-SS-14 (2000 Ci/mmol) was incubated for 60 rain 
at 30°C with or without unlabeled SS-14 in a final volume of 200pl. 
The incubation was terminated by centrifugation at 13,000 x g for 
1 min, the supernatant was aspirated and the pellet washed with 1.25 ml 
ice-cold incubation buffer. Tissue-bound radioactivity was determined 
following a second centrifugation a d aspiration. Non-specific binding 
was defined as binding in the presence of IBM unlabeled somatostatin. 
The effect of the guanidine nucleotide analogue, GTPyS, on [LzsI]Tyr11- 
SS-14 binding was studied as above at a ligand concentration f 30 pM 
with the inclusion of a range of GTPTS concentrations (1 nM-100 pM) 
in the assay buffer. All assays were performed in triplicates. Protein 
determinations were measured by the method of Lowry et al. [11]. 
3. Resu l ts  
Various cell lines were examined in an initial screening proce- 
dure for expression of preproSS-mRNA by Northern blot anal- 
ysis using a 32P-labeled rat preproSS cRNA-probe.  One human 
neuroblastoma, LA-N-2, among several differentiated and 
non-differentiated cell lines gave a positive hybridization signal. 
The following cell lines did not express detectable levels of 
preproSS-mRNA: SH-SY5Y, SK-N-MC,  SK-EP (Fig. 1), LA- 
N- l ,  LA-N-5, IMR-32 and SK-N-BE2 (data not shown). The 
positive result of the screening procedure was confirmed by 
hybridization to a 48mer oligodeoxynucleotide probe. The 
analysis revealed the presence of a single transcript (~ 850 nucle- 
otides) which migrated in parallel with preproSS-mRNA de- 
tected in tota l -mRNA prepared from rat brain tissue (Fig. 1). 
The LA-N-2 cell line was also found to contain SS-ir in pelleted 
cells at a concentrat ion o f -2  fmol/yg protein. Characterization 
of the cellular SS-ir by gel permeation chromatography (Se- 
phadex G-50 column, superfine, l l0x  1.5 cm) and measure- 
ments with a C-terminal directed antisera of the fractionated 
material showed presence of several immunoreactive peptide 
fragments. The elution profile was compared with SS-ir ex- 
tracted from the rat hypothalamus. Hypothalamic tissue con- 
tained three major peaks of  SS-ir. The predominant peak coe- 
luted with SS-14 (Mr 1,600), the median peak with SS-28 (Mr,. 
3,000) while the first peak had an apparent molecular weight 
of 15,000 (Fig. 2a). The elution profile of SS-ir extracted from 
the neuroblastoma LA-N-2 cell line was different (Fig. 2b). The 
28S 
18S 
1 2 3 4 5  
Fig. 1. Total mRNA (10 pg) prepared from various neuroblastoma cell 
lines (LA-N-2 (1), SK-N-MC (2), SH-SY5Y (3), SK-EP (4)) and rat 
brain tissue (5) hybridized with a 32p-labeled preproSS-oligodeoxynu- 
cleotide probe. The RNA samples were separated on a denaturing 1.2% 
formaldehyde-agarose gel and blotted onto Hybond-N+-filter. The po- 
sitions of 28S and 18S rRNA are indicated in the figure. 
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last peak corresponded to synthetic SS-28, while the two larger 
peaks had apparent molecular weights of 6,000 and 15,000 Da. 
Pooled SS-ir material from both of these two peaks were meas- 
urable with a N-terminal directed antisera 2098 (recognition 
sequence aa 20-36 [12]). The first peak (15,000 Da) eluted at 
identical position to the prohormonal form detected in the rat 
hypothalamus. Presence of pepstatin during detachment of the 
cells (1/aM) and acetic acid extraction (0.15 raM) of pelleted 
cells abolished the 6 kDa peak. No immunoreactivity was de- 
tected in fractions corresponding to synthetic SS-14. The re- 
lease of SS-ir into the cell medium was ~0.3 fmol//ag protein/h 
following a 4 h incubation period with fresh medium. Fresh cell 
medium was absent of SS-ir when checked with the C-terminal 
directed antisera. Specific binding of [~25IlTyrl LSS-14 to synap- 
tosomal membrane preparations of LA-N-2 cells was observed 
with a rapid association kinetics, reaching half-maximal levels 
within 10 rain (data not shown). [125I]Tyr:LSS-14 binding was 
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Fig. 3. (a) [:25I]Tyr~-SS-14 binding to synaptosomal membrane prepa- 
rations of LA-N-2 cells with increasing concentration of ligand. Total 
(m), specific (*) and non-specific (~) binding were measured as de- 
scribed in section 2. Values were obtained from three independent 
experiments. Each point represents he mean of three determinations. 
(b) Scatchard transformation f specific [:25I]Tyr:I-SS-14 binding data 
in (a). 
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Fig. 2. Sephadex G-50 (superfine, 110 × 1.5 cm) gel permeation chrom- 
atography performed on rat hypothalamic t ssue (a) (70 mg tissue) and 
pelleted LA-N-2 cells extracted in 1 M HAc, in absence (=) or presence 
([]) of 0.5 mM pepstatin (b) (~ 108 cells). The SS-immunoreactivity was 
eluted with 0.1 M acetic acid at a flow rate of~8 ml/h and analyzed with 
a C-terminal directed antisera for SS-14 (Amersham, UK) in fractions 
of 2 ml. The arrows indicate different molecular weight markers: 
(a) blue dextran (Mr = 200,000), (b), cytochrome c (M r = 12,400), 
(c) aprotinin (Mr = 6,500), (d) glucagon (M, = 3,500), (e) sodium chlor- 
ide (M r = 58). 
concentrations. Specific binding was saturable, while non-spe- 
cific binding increased linearly with increasing concentration of
ligand (Fig. 3a). Scatchard analysis was linear and the Hill 
coefficient (0.93 -+ 0.01 (n = 3)) was close to unity, indicating a
single class of high-affinity binding sites. The data was fitted 
into a one-site model with K d and Br~ax of 0.27 -+ 0.03 nM and 
45 _+ 1 fmol/mg protein, respectively (n = 3, Fig. 3b). Further- 
more the sensitivity of G-protein uncoupling of [125I]TyrlLSS - 
14 specific binding was studied by adding different concentra- 
tions of GTPyS to the incubation mixture. The stable guanidine 
nucleotide analogue, GTPyS, partially inhibited specific bind- 
ing in a concentration-dependent manner with an affinity of 9.7 
nM and a maximum inhibition of 30% (Fig. 4). 
4. Discussion 
The present study describes the characterization f a neuro- 
blastoma cell line with a somatostatinergic phenotype. Previous 
studies have shown that neuroblastomas may express omato- 
statin receptors [13-14], however to our knowledge there has 
been no reports on undifferentiated human neuroblastomas 
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Fig. 4. % specific [125I]Tyrl ~-SS-14 binding to synaptosomal membrane 
preparations ofLA-N-2 cells with increasing concentration fGTP),S. 
Total binding and non-specific binding in the absence of GTPyS was 
3137 + 73 cpm and 992 + 52 cpm respectively (mean + S.E.M.). Non- 
specific binding was defined as binding in the presence of lCtM unla- 
beled SS-14. 
containing preproSS-mRNA and SS-ir peptides. Our findings 
suggest that this phenotypic feature is rare, since various non- 
differentiated and differentiated cell lines tested were negative 
for preproSS-mRNA expression. Northern blot analysis re- 
vealed the expression of a single transcript with a estimated size 
of ~ 850 bp, in agreement with previous human and rodent mo- 
lecular cloning studies [15-16]. Gel permeation chromatogra- 
phy performed on cell pellet extracts from the neuroblastoma 
LA-N-2 resulted in one peak with an apparent molecular 
weight of 15 kDa using a C-terminal antisera. The elution 
position was identical with the first peak detected in hypotha- 
lamic tissue extracts, previuosly shown to represent a 
prohormonal form [17]. Furthermore pooled material of this 
peak was shown to have reactive pitopes against a N-terminal 
antisera 2098 (recognition sequence aa 20-36 [12]) suggesting 
identity with the prohormone, proSS(1-92), which is generated 
by removal of the N-terminal signal sequence. The estimated 
molecular weight of the plausible prohormone found in this 
study as well as other studies [17 18] was too high compared 
with the actual molecular weight deduced from sequence anal- 
ysis (Mr 10,388). This variation is likely due to some interfer- 
ence of the prohormone with the Sephadex gel matrix. The 
second peak identified with the C-terminal directed antisera 
had an apparent molecular weight of 6 kDa and showed N- 
terminal immunoreactivity against he antisera 2098. A SS-ir 
fragment of similar size has been previously identified in the rat 
brain [19-20]. This fragment probably corresponds to 
proSS(33-92) generated through cleavage at the Leu32-Leu33 
bond, although the genuity of this position as a post-transla- 
tional processing event has been questioned [21]. Inhibition of 
aspartate proteases with pepstatin during the extraction proce- 
dures eliminated the formation of this SS-ir form, consistent 
with previous findings [21]. The third peak eluted at a position 
identical to the peak of SS-28 detected in the hypothalamic 
tissue extract. The most striking difference compared to the rat 
hypothalamic tissue was the absence of the SS-14-ir fragment 
in the LA-N-2 cell extract. The most probable xplanation is
dissimilarities in activity of processing enzymes, which could be 
caused by different intravesicular milieu or basal expression of 
critical processing enzymes. The presence of independent proc- 
essing pathways resulting in two separate nd-products (SS-28 
and SS-14) with possibly diverse transmittor function are evi- 
dent [21, 22], although SS-28 may serve as a substrate for SS-14 
through cleavage by converting enzyme at the dibasic amino 
acids (Arg~3-Lys14) [23]. The subtilisin-like serine endoprotease, 
PC1, is likely to convert proSS(1-92) into SS-14, since expres- 
sion of PC1 in COS-7 cells increased SS-14-ir in cells and me- 
dium [24]. Provided that e.g. differentiating conditions of the 
LA-N-2 cell line could activate the critical processing enzyme 
the current finding raises the possibility to identify additional 
genes by means of subtractive cDNA-cloning. 
SS-ir peptides have been shown to regulate diverse signalling 
pathways uch as adenylyl cyclase activity, Ca 2+ and K+-cur - 
rents [25]. These cellular actions are mediated by membrane 
bound receptors frequently coupled to pertussis toxin sensitive 
G-proteins. The present data demonstrates xpression of high- 
affinity [125I]Tyr~I_SS. 14binding sites with sensitivity to G-pro- 
tein uncoupling in the neuroblastoma LA-N-2, which is charac- 
teristic for SS-receptors. Partial inhibition of specific binding 
by GTPyS at similar concentrations have been previously ob- 
served in transfection systems [26] as well as in rat brain tissue 
[27]. Five different SS receptor subtypes, all belonging to the 
family of G-protein coupled receptors, have been cloned during 
the last years [28]. Signal transduction studies performed on the 
subtype receptors in transfection systems are confusing. A re- 
cent report illustrates that all SS receptor subtypes are capable 
of G-protein mediated adenylyl cyclase inhibition provided that 
the receptors are expressed in cellular strains expressing the 
proper inhibitory G-proteins [29]. Thus conclusion on particu- 
lar SS-receptor subtype/subtypes expressed in the cell line re- 
quires further molecular biology studies or access to non-com- 
mercial igands with subtype-specificity. The LA-N-2 cell line, 
originally derived from a primary neuroblastoma tumor, was 
established by Seeger et al. [30]. Later studies have demon- 
strated expression of cholinergic phenotype markers in this cell 
line, such as choline acetyltransferase (CHAT) activity [31], 
choline uptake, high levels of acetylcholine and potassium in- 
duced release of the transmittor [32]. Activation of phospholip- 
ase C and D by carbachol was inhibited by atropine indicating 
expression of cholinergic receptors by the LA-N-2 cell line [33]. 
Furthermore the cells responded to retinoic acid [31], ChAT 
developmental factor and basic fibroblast growth factor with 
altered ChAT activity [34]. 
Human neuroblastoma cell lines are frequently used in stud- 
ies on neuronal functions. The homogenous populations of 
cells is particularly advantageous when elucidating regulatory 
mechanisms, uch as transcriptional regulation [35], translation 
and prohormonal processing. The findings of attenuated matu- 
ration of peptide processing in transcriptionally active systems 
implies that these events might be separately regulated [36]. The 
identification of a cell line expressing somatostatinergic pheno- 
type markers enables uch regulatory studies on somatostatin 
biosynthesis. Furthermore the previous findings of various 
cholinergic markers in the LA-N-2 cell line renders possibilities 
to investigate interactions between the somatostatinergic and 
cholinergic systems. Such studies are of marked interest since 
dysfunctions of the cholinergic basal forebrain eurons as well 
as cortical and hippocampal SS-ir interneurons have been con- 
sistently observed in Alzheimer's disease. 
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